Transcript NC BioStart Draft Strategic Plan

NC BioStart
Translation through Commercialization
1
Who we are
Dr. Richard Boucher
Don Rose, Ph.D.
Ilona Ori
Justin Brown, Ph.D.
Executive Director
Director
Program Assistant
Visiting Scholar, Entrepreneurship
Entrepreneurs-in-Residence
• Tom Mercolino, Ph.D
• Joel Shaffer, Ph.D.
• Perry Genova, Ph.D.
2
Rationale
Value of University Startups
• Translation through Commercialization
• Faculty Recruitment and Retention
• Increase Value of University Assets
• Economic Development
Build on current efforts at UNC to foster startups
• Launching the Venture (KFBS)
• Carolina Express License (OTD)
3
Program Overview
Mission
• Facilitate and accelerate University startups
Scope
• Life science (drugs, devices, diagnostics, tools)
Breadth
• Today: UNC-CH campus
• Future: All state-supported campuses
Location and Funding
• NC Translational and Clinical Sciences Institute
o Home of NIH CTSA Grant (Etta Pisano, PI)
4
NC BioStart
Education
• Bio-Launch the Venture
• Commercialization Webinars
Mentoring
• Entrepreneurs-in-Residence
• Faculty Mentors
Connecting
• External Advisory Board
• Emerging Company Showcase
• First Look Forum
Funding
Incubating
• TraCS Pilot Grants
• BioStart Commercialization Grants
• Incorporation and Marketing Services
• Executive-in-Residence Program
DRAFT
Tom Mercolino
PhD (UNC’88) – Microbiology & Immunology
BS – Chemistry
Registered Patent Agent
• >25 Years in Pharma & Diagnostics R&D Management
• Becton Dickinson
• Johnson & Johnson
• Entrepreneur
•Founder & CEO of CertiRx
7
Tom Mercolino
Representative Client Companies
• Rheomics - early
• College of Arts& Sciences (Prof. Physics Department)
• Re-focused technology platform to high-value applications
• Hepa Ca Dx - nascent
• UNC Gillings School of Global Public Health (PhD Student)
• organizing clinical proof of principle
• X-In8 - established
• School of Medicine (Prof. surgery)
• Id and resolution of potential patent issue in partnership with OTD
8
Joel Shaffer
Entrepreneur in Residence
for Therapeutics
9
Resume
• 5 yrs at American Critical Care (DuPont)
• 17 yrs at Glaxo (GW, GSK)
• Business Development for Metabolic Diseases
• Head of Pharmacology
• High-throughput screening
• Preclinical Project leader
• R&D in Cardiovascular, Oncology, Urology,
Metabolic Diseases
10
Entrepreneur-in-Residence at UNC May 2009
Advising 7 UNC clients
• Enci Therapeutics
• Hibernaid
• Novolipid
• Synereca
o (Scott Singleton, Ph.D. Med. Chem. natural prod.)
• G-zero
o (Ned Sharpless, M.D. Medicine, genetics)
• Matt Redinbo, Ph.D. Chemistry, structural chemistry
• Mark Zylka, Ph.D. Cell & Molecular Physiology
11
Enci Therapeutics
• Cam Patterson, M.D. and Nancy DeMore, M.D.
• Discovery of new angiogenesis factor (SFRP2)
• Developed a mouse mAb
• The antibody blunts tumor growth
• How does this target compare to VEGF?
• How do we make a human mAb for clinical testing?
12
Hibernaid
• Larry Katz, M.D.
• Has studied hypothermia mechanisms for years
• Ice baths improve outcome for pts with cardiac arrest
• Discovered that certain agents used in combination
(unexpectedly) lower the body’s temperature set point
• Determined a fixed combination of agents will:
• Lower temp by 4-5 oC
• Increase survival after acute cardiac arrest in rats and
pigs
• Improve CNS performance post injury
• Will this benefit patients suffering from reperfusion
injury?
13
Novolipid
• Mike Hackett and Deepak Gopalakrishna
• Graduate students, Pharmacy and Molecular Biology
• Discovered that they could covalently attach
cytotoxic chemotherapeutic drugs to small lipids
which have high affinity to albumin
• Longer half-life
• Less systemic toxicity of drug
• No need for toxic solvents
• Better tumor penetration
• Will this show superior effects in animals and
humans?
14
Perry Genova
•
•
•
•
•
MS, PhD Biomedical Engineering
BS EE, BME
Serial entrepreneur (IEP, Quill, Oncoscope)
Global VP – GSK (MDI business – France)
VP – Kos Pharmaceuticals
• Inhaled product development including insulin
• Worked for Adrian Adams (CEO – Inspire)
15
Katharos – Improving care for dialysis patients
•
•
•
•
•
•
•
•
Melanie Joy (UNC) and Marian McCord (NCSU)
Addresses large unmet need (160,000 patients)
Remove excess phosphate from blood during dialysis
High phosphate associated with morbidity and
mortality
Technology combines phosphate adsorption
chemistry with filtration science
Improved compliance, no side effects
TraCS grant supported feasibility work
TAM = 25M devices, $2.5B market
Contact Information
Don Rose
Director, NC BioStart
[email protected]
www.ncbiostart.com
Ilona Ori
Program Assistant
[email protected]
919-843-3304
Upcoming Events
Commercialization Webinar
• “Incorporation and Founder’s Stock”
• Ken Eheman and Anthony Williams, WRYP
• March 15th, 12 – 1 pm
Emerging Company Showcase
• April 12th, 6 pm, Kenan-Flagler Business School
17